原噬菌体疫苗对脑胶质瘤研究新进展
发布日期：2014年1月27日
The results of Agenus’ Prophage vaccine Phase 2 study, published last month in NeuroOncology,demonstrated that more than 90% of the patients treated with the vaccine candidate were alive at six months. The median overall survival in these patients was approximately 11 months.
The results of the Phase 2 trial have garnered the support of the National Cancer Institute (NCI). The NCI is funding the largest cancer vaccine trialinvestigating Prophage vaccine in combination with Avastin® (bevacizumab) in patientswith recurrent glioblastoma. The study is
actively enrolling and will offer the opportunity to provide important data to validate assessments of biomarkers and imaging criteria, which is needed to advance the understanding of treatment for patients with GBM.
For more information about Prophage vaccines and Agenus’ heat shock protein platform, please visit http://agenusbio.com/science/prophage.php.